ERBB2 and breast cancer: In HER2+ BC with brain metastases, resistance to PI3K inhibitors caused by HER2 amplification and PIK3CA mutations can be alleviated by inhibiting HER3 activity both in vitro and in vivo, indicating that HER3 promotes PI3K-mediated brain metastasis [93].